GPs 'are voting with their feet' as they struggle to meet current demands
Deutsche Bank issues report about the advantages of 'PfizerKline'
The healthcare giant plans to file at least 10 new molecular entities by 2019, each with the potential to exceed $1 billion in revenue.
Deal could be worth $A750 million ($600 million) for the NASH treatment
Biotech medicines now make up around half of the company’s pipeline
Stock-and-cash deal will create a major player in US generics market
The Academy of Medical Royal Colleges is bringing a US initiative to get doctors to stop using interventions with no benefit to the UK
The compound shrank tumours in people with advanced ALK-positive non-small cell lung cancer whose disease had progressed following treatment with Pfizer’s Xalkori.
The Scottish Medicines Consortium has given the green light to seven new medicines for use on the NHS
The firm, best-known for the hugely expensive ultra-rare blood disease treatment Soliris (eculizumab), is building its first ever biologics manufacturing plant outside the USA
GlaxoSmithKline has teamed up with the University of North Carolina at Chapel Hill in a 'unique public-private partnership'
Exp. Medical Reps and trainees. KAMs; eDetailing Reps Nationwide Opportunities
Click here to apply now!
2 x Respiratory Med Rep!
Click here to apply!
Nurse Advisor Roles
Click here to apply now
Find your next position today!
Click here to apply
Contracts and Pricing Manager
No running polls, please check backsoon.
Increase your knowledge. Browse the Pf Archive.
Read Pf now
Looking to make a move? Find your next job here.
click here to createan account
Need career advice? Visit our Career Centre.